Banyan Biomarkers Receives Contract by U.S. Department of Defense for Banyan BTI™

Banyan Biomarkers Receives Contract by U.S. Department of Defense for Banyan BTI™ (BusinessWire)

UF startup Banyan Biomarkers, Inc., a pioneer in developing biomarkers for mild traumatic brain injury (TBI), has been awarded a contract by the U.S. Department of Defense (DOD) to procure the Banyan Brain Trauma Indicator® (Banyan BTI™). Banyan Biomarkers is a graduate of UF Innovate | Sid Martin Biotech.

The Banyan BTI is a diagnostic blood test used to rule out the need for a head CT scan in patients 18 years of age and older with a suspected TBI. Per the terms of the contract, the DOD has ordered Banyan BTI tests for use in military installations that may include Fort Bragg, Fort Carson, Fort Hood, Fort Benning, Joint-Base San Antonio, Camp Pendleton, Fort Bliss, Fort Campbell, and Camp Lejeune.

“Several years ago, the U.S. Department of Defense made a commitment to support research and development of a blood test that provides objective data to healthcare providers when evaluating patients with a traumatic brain injury,” said Henry L. Nordhoff, Chairman and CEO of Banyan Biomarkers. “Today, we are proud to deliver on that commitment and provide the Banyan BTI test to help medical professionals more effectively manage soldiers who have suspected TBI.”

Learn more about Banyan Biomarkers Receives Contract by U.S. Department of Defense for Banyan BTI™.